Rosetta Genomics, UC Davis Partner on Patient Response to Bladder Cancer Treatment

The company and university are developing and validating a microRNA profile for muscle-invasive bladder cancer that may be used to predict response to neoadjuvant chemotherapies.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.